Study: Topical Administration of Cannabinoids Treats Intractable Leg Ulcers

Toronto, Canada: The administration of a proprietary blend of topical cannabinoids, terpenes, and flavonoids resulted in wound healing in a pair of elderly patients with treatment-resistant leg ulcers, according to data published in the publication International Wound Journal.

A team of Canadian scientists assessed the daily topical application of cannabinoids on wound healing and wound-related pain in two patients with severe and persistent leg ulcers. In one patient, cannabinoid treatment resulted in complete wound closure in 77 days; in second patient, wound closure was achieved in 74 days. Patients reduced and eventually eliminated their use of conventional analgesics over the course of treatment.

Researchers reported, “This is the first study to report the use of TCBM [Topical Cannabis-Based Medicines] to promote complete integumentary wound closure in human subjects, specifically, two Caucasian females with a mean age of 77 years, with three lower limbs afflicted with intractable and biopsy proven NUC [Non-Uremic Calciphylaxis].”

They concluded: “Topical Cannabis-Based Medicines, applied to both wound beds and peri-wound tissues, represent a promising novel, non-invasive, and safe treatment option for NUC leg ulcers. The ease and simplicity of its application also allows for potential self-application and self-titration by patients. Given that TCBM demonstrated both rapid wound closure and relief of wound-related pain, in very challenging wounds such as NUC, among highly complex patients, they may be poised for an even broader role within overall integumentary and wound management.”

A pair of prior case reports have similarly shown that the topical administration of cannabinoids facilitates wound healing and reduces the use of analgesics in patients with the rare skin-blistering disease epidermolysis bullosa.

Full text of the study, “Topical cannabis-based medicines – A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial,” appears in International Wound Journal.